For the quarter ended September 2026, ResMed (RMD Quick QuoteRMD - Free Report) reported revenue of $1.41 billion, up 5.9% over the same period last year. EPS came in at $2.91, compared to $2.55 in the year-ago quarter.

The reported revenue represents a surprise of +1.66% over the Zacks Consensus Estimate of $1.39 billion. With the consensus EPS estimate being $2.67, the EPS surprise was +8.99%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how ResMed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Americas- Devices: $436 million compared to the $434.08 million average estimate based on four analysts. The reported number represents a change of +5.5% year over year.
• Americas- Masks and other: $397 million versus the four-analyst average estimate of $393.72 million. The reported number represents a year-over-year change of +9.9%.
• Rest of World- Total: $426 million versus $429.11 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.9% change.
• Rest of World- Devices: $283 million versus $285.55 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6% change.
• Rest of World- Masks and other: $143 million compared to the $143.57 million average estimate based on four analysts. The reported number represents a change of +11.9% year over year.
• Americas- Total: $833 million versus the four-analyst average estimate of $827.81 million. The reported number represents a year-over-year change of +7.5%.
• Global revenue- Total Sleep and Breathing Health: $1.26 billion versus the six-analyst average estimate of $1.25 billion. The reported number represents a year-over-year change of +7.8%.
• Global revenue- Residential Care Software: $155 million versus the six-analyst average estimate of $144.46 million. The reported number represents a year-over-year change of -6.7%.
• Global revenue- Total Devices: $720 million versus the five-analyst average estimate of $714.5 million. The reported number represents a year-over-year change of +5.8%.
• Global revenue- Total Masks and other: $540 million versus $535.83 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +10.4% change.

View all Key Company Metrics for ResMed here>>>

Shares of ResMed have returned +14.3% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.